List view / Grid view

Perjeta (pertuzumab)

Filter the results



UPDATE: The Cancer Drugs Fund

1 March 2017 | By Niamh Louise Marriott, Digital Editor

This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).


Perjecta (pertuzumab) and Kadcycla (trastuzumab emtansine) remain available through Cancer Drugs Fund, but Avastin (bevacizumab) denied

13 January 2015 | By Porter Novelli Limited

Roche welcomes the announcement from NHS England that patients can continue to access our breast cancer medicines Perjeta, Kadcyla and Avastin via the Cancer Drugs Fund (CDF), but is extremely disappointed that patients with advanced bowel and ovarian cancer will now be denied Avastin on the NHS, following their review…


Roche obtains EU approval for PERJETA

5 March 2013 | By Roche

Roche announced that the EMA has approved PERJETA (pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC)...